

Risk Evaluation and Mitigation Strategy (REMS) Document

A. Adempas¹ REMS Program

I. Administrative Information

Application Number: NDA 204819

Application Holder: Bayer HealthCare Pharmaceuticals, Inc.

Initial REMS Approval: 10/2013

Most Recent REMS Update: 11/2020

II. REMS Goal

The goal of the Adempas REMS Program is to mitigate the risk of embryo-fetal toxicity associated with Adempas by:

1. Ensuring prescribers are educated on the following:
 - the risk of embryo-fetal toxicity
2. Ensuring prescribers are educated on and adhere to the following:
 - counseling patients about the risk and the need for monthly monitoring
 - enrolling patients in the Adempas REMS Program
 - monitoring patients at baseline and monthly
3. Ensuring that pharmacies are educated on the following:
 - the risk of embryo-fetal toxicity
4. Ensuring that pharmacies are educated on and adhere to the following:
 - confirming that the appropriate patient monitoring and counseling has occurred before dispensing Adempas
5. Ensuring that patients are informed about:
 - the risk of embryo-fetal toxicity
 - appropriate baseline and monthly patient monitoring
 - appropriate contraception

III. REMS Requirements

Bayer HealthCare Pharmaceuticals, Inc. must ensure that healthcare providers, patients, pharmacies, and wholesalers-distributors comply with the following requirements:

1. Healthcare Providers who prescribe Adempas must:

¹ The Adempas-specific requirements contained in this document apply until the date of full approval of the first abbreviated new drug application (ANDA) joining a shared system REMS with Adempas.

To become certified to prescribe	<ol style="list-style-type: none"> 1. Review the drug's Prescribing Information. 2. Review the following: Prescriber and Pharmacy Guide. 3. Enroll in the REMS by completing the Prescriber Enrollment and Agreement Form and submitting it to the REMS Program.
Before treatment initiation (first dose)	<ol style="list-style-type: none"> 4. For all females: Assess the patient's reproductive status using the definitions in the Prescriber and Pharmacy Guide. Document and submit the results to the REMS Program using the Patient Enrollment and Consent Form. 5. For all females: Counsel the patient that the drug is only available through a restricted distribution program. 6. For females of reproductive potential: Counsel the patient on the risk of embryo-fetal toxicity, the need to use effective contraception during treatment and for one month following treatment discontinuation, emergency contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant using the Guide for Female Patients. 7. For females of reproductive potential: Assess the patient's pregnancy status by ordering and reviewing her pregnancy test result. 8. For pre-pubertal females: Counsel the patient on the risk of embryo-fetal toxicity and to immediately contact her prescriber if she begins to menstruate - using the Guide for Female Patients. 9. Enroll all female patients by completing and submitting the Patient Enrollment and Consent Form and submitting it to the REMS Program.
During treatment; before each prescription	<ol style="list-style-type: none"> 10. For females of reproductive potential: Counsel the patient if she is not complying with the required testing or if she is not using effective contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant. 11. For females of reproductive potential: Assess the patient's pregnancy status by ordering and reviewing her pregnancy test result.
During treatment; at least annually	<ol style="list-style-type: none"> 12. For pre-pubertal females at least age 8 years or older: Document reproductive status and submit to the REMS Program using the Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form.
After treatment discontinuation; one month	<ol style="list-style-type: none"> 13. For females of reproductive potential: Assess the patient's pregnancy status by ordering and reviewing her pregnancy test result.

At all times	14. For pre-pubertal females: Assess the patient's reproductive status.
	15. Report pregnancies to Bayer HealthCare Pharmaceuticals, Inc.
At all times; within 10 business days	16. Report a change or misclassification in reproductive status to the REMS Program using the Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form .

2. Females of reproductive potential who are prescribed Adempas:

Before treatment initiation	<ol style="list-style-type: none"> 1. Review the Guide for Female Patients. 2. Get a pregnancy test. 3. Enroll in the REMS Program by completing the Patient Enrollment and Consent Form with the prescriber. Enrollment information will be provided to the REMS Program. 4. Receive counseling from the prescriber on the risk of embryo-fetal toxicity, the need to use effective contraception during treatment and for one month following treatment discontinuation, emergency contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant using the Guide for Female Patients. 5. Adhere to the safe use condition: Communicate with the pharmacy to confirm completion of pregnancy testing.
Before dispensing	<ol style="list-style-type: none"> 6. Receive counseling from the pharmacy or the prescriber who dispenses Adempas on the risk of embryo-fetal toxicity, the need for effective contraception during treatment and for one month after stopping treatment, to get monthly pregnancy tests, and to report a pregnancy immediately. 7. Get a pregnancy test. 8. Adhere to the safe use condition: Communicate with the pharmacy to confirm completion of pregnancy testing.
During treatment and after treatment discontinuation for one month	<ol style="list-style-type: none"> 9. Adhere to the safe use condition: Use effective contraception as described in the Guide for Female Patients. 10. Agree to be contacted by the manufacturer if you become pregnant.
After treatment discontinuation; one month	<ol style="list-style-type: none"> 11. Get a pregnancy test.
At all times	<ol style="list-style-type: none"> 12. Inform the prescriber immediately if you miss a menstrual period or suspect a pregnancy.

3. Pre-pubertal females who are prescribed Adempas:

-
- | | |
|-----------------------------|--|
| Before treatment initiation | <ol style="list-style-type: none">1. Review the Guide for Female Patients.2. Enroll in the REMS Program by completing the Patient Enrollment and Consent Form with the prescriber. Enrollment information will be provided to the REMS Program.3. Receive counseling from the prescriber on the risk of embryo-fetal toxicity and to immediately contact your prescriber if you begin to menstruate using the Guide for Female Patients. |
|-----------------------------|--|
-

- | | |
|--------------|--|
| At all times | <ol style="list-style-type: none">4. If over the age of 8: Be monitored for a change in reproductive status.5. Inform the prescriber if there is change in reproductive status. |
|--------------|--|
-

4. Post-menopausal females or females with other medical reason for permanent, irreversible infertility who are prescribed Adempas:

-
- | | |
|-----------------------------|--|
| Before treatment initiation | <ol style="list-style-type: none">1. Review the Guide for Female Patients.2. Enroll in the REMS Program by completing the Patient Enrollment and Consent Form with the prescriber. Enrollment information will be provided to the REMS Program. |
|-----------------------------|--|
-

- | | |
|--------------|--|
| At all times | <ol style="list-style-type: none">3. Inform the prescriber if there is a change in your reproductive status. |
|--------------|--|
-

5. Outpatient Pharmacies and prescribers that dispense Adempas must:

To become certified to dispense

1. For outpatient pharmacies: Designate an authorized representative to carry out the certification process and oversee implementation and compliance with the REMS Program on behalf of the outpatient pharmacy.
2. For prescribers who dispense: Complete the certified dispenser section of the [Prescriber Enrollment and Agreement Form](#).
3. Review the [Prescriber and Pharmacy Guide](#).
4. Train all relevant staff involved in dispensing on the Adempas REMS Program requirements, procedures, and REMS materials using the [Prescriber and Pharmacy Guide](#).
5. Establish processes and procedures to verify the female patient is enrolled, the reproductive status of the patient has not changed, the prescriber is certified, and if the prescriber dispensed a 30 days' supply of Adempas.
6. For females of reproductive potential: Establish processes and procedures to verify that pregnancy testing is complete or the prescriber authorizes the refill through the processes and procedures established as a requirement of the REMS program.

Before dispensing

7. For females of reproductive potential: Counsel the patient on the risk of embryo-fetal toxicity, the need to use effective contraception during treatment and for one month after stopping treatment, to get monthly pregnancy tests, and inform her prescriber immediately if she misses a menstrual period or suspects she may be pregnant.
 8. Verify the female patient is enrolled, the reproductive status has not changed, the prescriber is certified, and if the prescriber dispensed a 30 days' supply of Adempas through the processes and procedures established as a requirement of the REMS Program.
 9. For females of reproductive potential: Verify that pregnancy testing is complete or the prescriber authorizes the refill through the processes and procedures established as a requirement of the REMS Program.
 10. For females of reproductive potential: Dispense no more than a 30-days' supply.
 11. For prescribers who dispense: Report dispensing Adempas to the REMS Program using the [Patient Enrollment and Consent Form](#).
-

At all times	<ol style="list-style-type: none"> 12. Report pregnancies to Bayer HealthCare Pharmaceuticals, Inc. 13. Not distribute, transfer, loan, or sell Adempas. 14. For outpatient pharmacies: Maintain and submit records of daily product dispensing data for females of reproductive potential. 15. Maintain records of all processes and procedures including compliance with those processes and procedures. 16. Comply with audits carried out by the manufacturer or a third party acting on behalf of the manufacturer to ensure that all processes and procedures are in place and are being followed.
--------------	---

6. Inpatient Pharmacies that dispense Adempas must:

To become certified to dispense	<ol style="list-style-type: none"> 1. Designate an authorized representative to carry out the certification process and oversee implementation and compliance with the REMS Program on behalf of the pharmacy. 2. Have the authorized representative enroll in the REMS Program by completing the Inpatient Pharmacy Enrollment Form and submitting it to the REMS Program. 3. Have the authorized representative review the Prescriber and Pharmacy Guide. 4. Train all relevant staff involved in dispensing Adempas on the REMS Program requirements, procedures and REMS materials using the Prescriber and Pharmacy Guide. 5. Establish processes and procedures to verify the female patient is enrolled in the REMS Program or will be enrolled prior to discharge, her reproductive status, and the female patient is under the supervision and care of a certified prescriber. 6. For females of reproductive potential: establish processes and procedures to verify pregnancy testing is complete and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately.
Before dispensing	<ol style="list-style-type: none"> 7. Verify the female patient is under the supervision and care of a certified prescriber, her reproductive status, and that she is enrolled or will be enrolled in the REMS Program prior to discharge through the processes and procedures established as a requirement of the REMS Program. 8. For females of reproductive potential: Verify pregnancy testing is complete, and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately through the processes and procedures established as a requirement of the REMS Program.
At discharge	<ol style="list-style-type: none"> 9. Verify female patient is enrolled in the REMS Program through the processes and procedures established as a requirement of the REMS. 10. Dispense no more than a 15-day's supply.

At all times	<ol style="list-style-type: none"> 11. Report pregnancies to Bayer HealthCare Pharmaceuticals, Inc. 12. Not distribute, transfer, loan, or sell Adempas. 13. Maintain records of all processes and procedures including compliance with those processes and procedures. 14. Comply with audits carried out by the manufacturer or a third party acting on behalf of the manufacturer to ensure that all processes and procedures are in place and are being followed.
--------------	---

7. Wholesalers-distributors that distribute Adempas must:

To be able to distribute	<ol style="list-style-type: none"> 1. Establish processes and procedures to ensure that the drug is distributed only to certified pharmacies and certified prescribers who can dispense Adempas. 2. Train all relevant staff involved in distribution on the Adempas REMS Program requirement.
At all times	<ol style="list-style-type: none"> 3. Distribute only to certified pharmacies and certified prescribers who can dispense Adempas. 4. Maintain records of drug distribution. 5. Comply with audits carried out by the manufacturer or a third party acting on behalf of the manufacturer to ensure that all processes and procedures are in place and are being followed.

Bayer HealthCare Pharmaceuticals, Inc must provide training to healthcare providers who prescribe Adempas.

The training includes the following educational material: [Prescriber and Pharmacy Guide](#). The training must be available online or by calling the REMS Program.

Bayer HealthCare Pharmaceuticals, Inc must provide training to pharmacies that dispense Adempas.

The training includes the following educational materials: [Prescriber and Pharmacy Guide](#). The training must be available online or by calling the REMS Program.

To support REMS Program operations, Bayer HealthCare Pharmaceuticals, Inc must:

1. Establish and maintain a REMS Program website, www.AdempasREMS.com. The REMS Program website must include the capability to complete prescriber and inpatient pharmacy certification or enrollment online, the capability to enroll and manage patients online, and the option to print the Prescribing Information, Medication Guide, and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS Program website. The REMS Program website must not link back to the promotional product website.
2. Make the REMS Program website fully operational and all REMS materials available through the REMS Program website or coordinating center within 90 calendar days of REMS modification approval (MM/YYYY).
3. Establish and maintain a REMS Program coordinating center for REMS participants at 1-866-228-3546.
4. Establish and maintain a validated, secure database of all REMS participants who are enrolled and/or certified in the Adempas REMS Program.
5. Ensure prescribers are able to certify by submitting a completed [Prescriber Enrollment and](#)

[Agreement Form](#) by fax, online and phone.

6. Ensure outpatient pharmacies are able to certify by contracting with the manufacturer and agreeing to comply with the requirements of the REMS Program.
7. Ensure inpatient pharmacies are able to certify by submitting a completed [Inpatient Pharmacy Enrollment Form](#) by fax, online and phone.
8. Ensure prescribers are able to report change in reproductive status by fax and online.
9. Ensure prescribers are able to complete the patient enrollment process by fax and online.
10. Ensure pharmacies are able to confirm patient enrollment, prescriber certification, and safe use conditions are met prior to dispensing Adempas by phone and online.
11. Ensure prescribers are able to report dispensing Adempas by fax and online.
12. Ensure pharmacies are able to enroll as inpatient (including, but not limited to, pharmacies in hospitals, long-term care facilities, and prisons) or as outpatient pharmacies.
13. Ensure pharmacies are able to confirm by phone and online if Adempas was dispensed by a prescriber.
14. Ensure inpatient pharmacies are able to contact the coordinating center for assistance in obtaining up to a 15 day supply of drug for a specific inpatient while the inpatient pharmacy completes the certification process.
15. Provide the [Prescriber Enrollment and Agreement Form](#) and [Prescriber and Pharmacy Guide](#) to prescribers who (1) attempt to prescribe Adempas and are not yet certified or (2) inquire about how to become certified.
16. Notify certified pharmacies of a patient's change or misclassification in reproductive status within one business day of receipt of a completed [Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form](#).
17. Provide certified prescribers access to the database of certified pharmacies and enrolled patients.
18. Provide certified pharmacies access to the database of certified prescribers and enrolled patients.

To ensure REMS participants' compliance with the REMS Program, Bayer HealthCare Pharmaceuticals, Inc must:

19. Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to records of: Adempas distribution and dispensing; certification of prescribers and pharmacies; enrolled patients; and audits of REMS pharmacies, prescribers who dispense, and wholesalers-distributors. These records must be readily available for FDA inspections.
20. Establish a plan for addressing noncompliance with REMS Program requirements.
21. Monitor prescribers, pharmacies, and wholesalers-distributors on an ongoing basis to ensure the requirements of the REMS are being met. Take corrective action if noncompliance is identified, including de-certification.
22. Audit all certified outpatient pharmacies and prescribers who dispense within 180 days after they become certified, to ensure that all REMS processes and procedures are in place, functioning, and support the REMS Program requirements.
23. Audit all wholesalers-distributors within 180 days after they become authorized to distribute, to ensure that all REMS processes and procedures are in place, functioning, and support the REMS

Program requirements.

24. Audit all certified outpatient pharmacies, wholesalers-distributors, the coordinating center for Adempas, at least 10% of certified inpatient pharmacies that have ordered Adempas annually and, audit, every 6 months, all prescribers who dispense to ensure that all REMS processes and procedures are in place, functioning, and support the REMS Program requirements.
25. Take reasonable steps to improve operation of and compliance with the requirements in the Adempas REMS Program based on monitoring and evaluation of the Adempas REMS Program.

IV. REMS Assessment Timetable

Bayer HealthCare Pharmaceuticals, Inc must submit REMS Assessments at 6 months and 12 months from the date of the initial REMS approval (10/18/2013), and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Bayer HealthCare Pharmaceuticals, Inc must submit each assessment so that it will be received by the FDA on or before the due date.

V. REMS Materials

The following materials are part of the Adempas REMS:

Enrollment Forms

Prescriber:

1. [Prescriber Enrollment and Agreement Form](#)

Patient:

2. [Patient Enrollment and Consent Form](#)

Pharmacy:

3. [Inpatient Pharmacy Enrollment Form](#)

Training and Educational Materials

Prescriber:

4. [Prescriber and Pharmacy Guide](#)

Patient:

5. [Guide for Female Patients](#)

Pharmacy:

6. [Prescriber and Pharmacy Guide](#)

Patient Care Form

7. [Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form](#)

Other Materials

8. [REMS Program website \(www.AdempasREMS.com\)](http://www.AdempasREMS.com)

Adempas REMS (Risk Evaluation and Mitigation Strategy)

Prescriber Enrollment and Agreement Form

In order to prescribe Adempas, prescribers must enroll in the Adempas REMS by completing this form. In order to receive samples of Adempas, prescribers must be enrolled in the Adempas REMS and agree to comply with the requirements for a Sample Dispensing Prescriber, detailed in the agreement below.

Access this form online at www.adempasREMS.com, fax this form to 1-855-662-5200 or call the Adempas REMS at 1-855-4ADEMPAS (1-855-423-3672).

Prescriber Information (* indicates required field)

First Name*:	Middle Initial:	Last Name*:	NPI*:
Specialty*: <input type="checkbox"/> Cardiology <input type="checkbox"/> Pulmonology <input type="checkbox"/> Other			Credentials*: <input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> Other with prescriptive authority
Practice/Facility Name:			
Address Line 1*:		Address Line 2:	
City*:		State*:	Zip code*:
Phone*:	Fax*:	Email*:	Preferred Method of Contact: <input type="checkbox"/> Phone <input type="checkbox"/> Email <input type="checkbox"/> Fax

Office Contact

First Name:	Last Name:	Email* (required if Office Contact is provided):
First Name:	Last Name:	Email* (required if Office Contact is provided):

Prescriber REMS Agreement

By signing below, you signify your understanding of the risks of Adempas treatment and your obligation as an Adempas prescriber to educate your female patients about the Adempas REMS, monitor them appropriately, and report any pregnancies to the Adempas REMS. Specifically, you attest to the following:

- I have reviewed the Adempas Prescribing Information and the *Prescriber and Pharmacy Guide*.
- For all Females, I will:
 - o determine the reproductive potential status of all female patients using the definitions provided in the *Prescriber and Pharmacy Guide*.
 - o advise all females that Adempas is only available through a restricted distribution program called the Adempas REMS.
 - o enroll all female patients into the Adempas REMS by completing the *Patient Enrollment Form* and submitting it to the REMS.
- For Females of Reproductive Potential, I will:
 - o counsel Females of Reproductive Potential (FRP) on Adempas risks, including serious birth defects; and review the *Guide for Female Patients* with the patient.
 - o counsel each FRP to immediately contact her prescriber if she misses a menstrual period or suspects pregnancy.
 - o order and review pregnancy tests for FRPs before the start of treatment, monthly during treatment, and for one month after stopping treatment.
 - o counsel each FRP to use effective contraception during Adempas treatment, and for one month after stopping treatment, and discuss her medical options in the event of unprotected sexual intercourse or known or suspected contraceptive failure using the *Guide for Female Patients*.
 - o counsel each FRP during treatment if she is not complying with the required testing or if she is not using effective contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant.
- For Pre-pubertal Females, I will:
 - o counsel the Pre-Pubertal Female (PPF) patient on the Adempas risks, including serious birth defects; and to immediately contact her prescriber if she begins to menstruate.
 - o review the *Guide for Female Patients* with the patient
 - o for PPF, regularly assess the reproductive status of each pre-pubertal female during their treatment with Adempas
 - o at least annually document the reproductive potential status for Pre-Pubertal Females who are at least 8 years of age and older by submitting a *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form*.
- At all times, I will:
 - o report any change or misclassification in reproductive status by submitting a *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form* within 10 business days of becoming aware of the change.
 - o provide documentation of compliance with program requirements
 - o notify Bayer of any pregnancies at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

REQUIRED	Prescriber Signature*:	Date* (MM/DD/YYYY):
-----------------	------------------------	---------------------

Prescriber REMS Agreement for Those Who Dispense Samples

- I will:
- follow the requirements of a prescriber as I have attested to on the *Prescriber Enrollment and Agreement Form* above
 - dispense Adempas to female patients only if the *Patient Enrollment and Consent Form* has been signed and submitted
 - report dispensing Adempas to the REMS using the *Patient Enrollment and Consent Form*
 - order and review a pregnancy test for FRP prior to dispensing Adempas
 - not distribute, transfer, loan, or sell Adempas
 - maintain records of all processes and procedures including compliance with those processes and procedures
 - comply with audits

REQUIRED	Prescriber Signature*:	Date* (MM/DD/YYYY):
-----------------	------------------------	---------------------

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact: Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.



Adempas REMS Patient Enrollment and Consent Form

Access this form online at www.adempasREMS.com, or fax this form to the Adempas REMS at 1-855-662-5200

1 Patient Information (* indicates required field)

First Name*:	Middle Initial:	Last Name*:	Birthdate* (MM/DD/YYYY):	Gender*: <input type="checkbox"/> Male <input type="checkbox"/> Female
Address Line 1*:			Address Line 2:	
City*:		State*:	Zip code*:	
Preferred Phone*:	Can we leave a message on this phone? <input type="checkbox"/> Yes <input type="checkbox"/> No		Preferred Time to Contact: <input type="checkbox"/> Day <input type="checkbox"/> Evening	
Cell/Alternate Phone:		Email:		
Alternate Contact Name:	Phone:	Relationship:		
<input type="checkbox"/> 1 mg Adempas Sample Dispensed* / Date: _____ <input type="checkbox"/> 0.5 mg Adempas Sample Dispensed* / Date: _____				

2 Statement of Medical Necessity (* indicates required field)

The following does not suggest approved uses or indications.

Diagnosis*:

Pulmonary arterial hypertension <input type="checkbox"/> I27.0 <input type="checkbox"/> I27.21	Chronic thromboembolic pulmonary hypertension I27.24 <input type="checkbox"/> Inoperable <input type="checkbox"/> Persistent/Recurrent	<input type="checkbox"/> OTHER (please specify) _____
---	--	---

Therapy Status:

<input type="checkbox"/> Initial therapy (monotherapy or in combination)
<input type="checkbox"/> Add-on therapy
<input type="checkbox"/> Transition from other therapy

3 Female Patient Agreement

For all Females: I understand that Adempas is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).
For Females Who Can Get Pregnant: I have been counseled on the risks of Adempas, including the risk of serious birth defects. I have read the *Guide for Female Patients*. Before treatment initiation, I understand that I will receive counseling from the prescriber on: the risk of serious birth defects, the need to use effective contraception during Adempas treatment and for one month after stopping Adempas treatment, my medical options in the event of unprotected sexual intercourse or known or suspected contraception failure, and to immediately contact my prescriber if I miss a menstrual period or suspect that I am pregnant. Before each prescription, I will receive counseling by the pharmacy or the prescriber who dispenses Adempas on the risk of serious birth defects, the need to use effective contraception during Adempas treatment and for one month after stopping Adempas treatment, to get monthly pregnancy tests, and to report a pregnancy immediately. Ensure that I have completed pregnancy testing before I started Adempas, monthly before each refill, and for one month after stopping Adempas. I understand that I may be contacted by Bayer and/or its agents and contractors to obtain information about my pregnancy. I will communicate with the pharmacy to confirm completion of pregnancy testing.
For Pre-Pubertal Females: I have been counseled on the risks of Adempas, including the risk of serious birth defects, and that I have read the *Guide for Female Patients*. I understand that I must immediately contact my healthcare provider if I get my menstrual period.
For Post-Menopausal Females: I have received and read the *Guide for Female Patients* and that I will inform my prescriber if there is a change in my reproductive status.
For Females with other medical reasons for permanent, irreversible infertility: I have received and read the *Guide for Female Patients* and that I will inform my prescriber if there is a change in my reproductive status.

REQUIRED FOR ALL FEMALE PATIENTS	Patient or Parent/Guardian Signature: _____	Date: _____
---	--	-------------

4 Prescriber Information (* indicates required field)

First Name*:	Last Name*:	NPI*:		
Practice/Facility Name (where you see this patient):				
Address Line 1*:		Address Line 2:		
City:	State:	Zip code:	Phone*:	State License #:

5 Prescriber Authorization

REQUIRED FOR ALL FEMALE PATIENTS	For female patients, please indicate the patient's current reproductive status below.
	<input type="checkbox"/> Female of NON-Reproductive Potential <input type="checkbox"/> Pre-Pubertal Female <input type="checkbox"/> Post-Menopausal Female <input type="checkbox"/> Female with other medical reasons for permanent, irreversible infertility
	OR
	<input type="checkbox"/> Female of Reproductive Potential If this patient is a Female of Reproductive Potential has a pregnancy test been completed prior to prescribing Adempas? <input type="checkbox"/> Yes <input type="checkbox"/> No

I certify that the information provided is accurate to the best of my knowledge. I certify that for female patients, I have provided the appropriate counseling and Adempas REMS materials, and I will continue to fulfill my obligations under the Adempas REMS Program. I understand that I may not delegate signature authority.

REQUIRED	Prescriber Signature*: _____	Date*:
-----------------	-------------------------------------	--------

Definitions:

Females of Reproductive Potential

- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential, I will:

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Females: Females who have passed through menopause. Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.
- Females with other medical reasons for permanent, irreversible infertility.

Prescriber Obligations under the Adempas REMS

For All Females, I will:

- determine the reproductive potential status of all female patients using the definitions provided in the *Prescriber and Pharmacy Guide*.
- advise all females that Adempas is only available through a restricted distribution program called the Adempas REMS.
- enroll all female patients into the Adempas REMS by completing the *Patient Enrollment and Consent Form* and submitting it to the REMS

For Females of Reproductive Potential, I will:

- counsel Females of Reproductive Potential (FRP) on Adempas risks, including serious birth defects; and review the *Guide for Female Patients* with the patient.
- counsel each FRP to immediately contact her prescriber if she misses a menstrual period or suspects pregnancy.
- order and review pregnancy tests for FRPs before the start of treatment, monthly during treatment, and for one month after stopping treatment.
- counsel each FRP to use effective contraception during Adempas treatment and for one month after stopping treatment and discuss her medical options in the event of unprotected sexual intercourse or known or suspected contraceptive failure using the *Guide for Female Patients*.
- counsel each FRP during treatment if she is not complying with the required testing or if she is not using effective contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant.

For Pre-Pubertal Females, I will:

- counsel the Pre-Pubertal Female (PPF) patient on the Adempas risks, including serious birth defects and to immediately contact her prescriber if she begins to menstruate
- Review the *Guide for Female Patients* with the patient.
- for PPF, regularly assess the reproductive status of each pre-pubertal female during their treatment with Adempas.

Submit this form online at www.adempasREMS.com or fax this form to 1-855-662-5200

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact: Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Phone: 1-855-4ADEMPAS (1-855-423-3672) www.adempasREMS.com Fax: 1-855-662-5200



Reference ID: 4709629

07 Feb 2020

Adempas REMS (Risk Evaluation and Mitigation Strategy)

Inpatient Pharmacy Enrollment Form

Due to a risk of fetal exposure and adverse fetal outcomes in females of reproductive potential prescribed Adempas, Adempas is available only through the Adempas REMS. The Adempas REMS is a component of a Risk Evaluation and Mitigation Strategy (REMS). In order for inpatients to receive Adempas, females as well as inpatient pharmacies that wish to stock this product, must be enrolled in the Adempas REMS and agree to comply with the requirements of the program.

Access this form online at www.adempasREMS.com, fax this form to 1-855-662-5200 or call the Adempas REMS at 1-855-4ADEMPAS (1-855-423-3672).

Inpatient Pharmacy Information (* Indicates required field)			
Type of facility*: <input type="checkbox"/> Hospital <input type="checkbox"/> Long-term Care Facility <input type="checkbox"/> Prison <input type="checkbox"/> Other _____			NPI*:
Facility Name*:			
Address Line 1*:		Address Line 2:	
City*:		State*:	Zip code*:
Phone*:		Fax*:	
Ship To Information (* Indicates required field)			
Ship To Address <input type="checkbox"/> Same as above		Ship To Contact Name*:	
Address Line 1*:		Address Line 2:	
City*:		State*:	Zip code*:
Phone*:		Fax*:	
Authorized Representative Information (* Indicates required field)			
First Name*:		Middle Initial:	Last Name*:
Position/Title: <input type="checkbox"/> Hospital Pharmacist <input type="checkbox"/> Head of P & T Committee <input type="checkbox"/> Other Title			
Phone*:		Fax*:	Email*:
Inpatient Pharmacy / Authorized Representative Acknowledgement			
<p>This inpatient pharmacy will:</p> <ul style="list-style-type: none">• establish processes and procedures to ensure the REMS requirements are met.• complete training in the Adempas REMS by reading the <i>Prescriber and Pharmacy Guide</i>.• assume responsibility for the training of all relevant staff in dispensing on the Adempas REMS requirements, procedures and Adempas REMS materials prior to dispensing Adempas, using the <i>Prescriber and Pharmacy Guide</i>.• establish processes and procedures to verify the female patient is enrolled in the REMS or will be enrolled prior to discharge, her reproductive status, and the female patient is under the supervision and care of a certified prescriber.• for females of reproductive potential: establish processes and procedures to verify pregnancy testing is complete and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately. <p>Before Dispensing:</p> <ul style="list-style-type: none">• verify the female patient is under the supervision and care of a certified prescriber, her reproductive status, and that she is enrolled or will be enrolled in the REMS prior to discharge through the processes and procedures established as a requirement of the REMS.• for females of reproductive potential: verify pregnancy testing is complete, and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately through the processes and procedures established as a requirement of the REMS. <p>At Discharge:</p> <ul style="list-style-type: none">• verify the female patient is enrolled in the REMS through the processes and procedures established as a requirement of the REMS.• dispense no more than a 15-day temporary supply of Adempas to any female patient upon discharge from the healthcare facility. <p>At all times:</p> <ul style="list-style-type: none">• not distribute, transfer, loan, or sell Adempas.• report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.• comply with audits by the manufacturer or a third party acting on behalf of the manufacturer to ensure all processes and procedures are in place and being followed.• maintain records of all processes and procedures including compliance with those processes and procedures. <p>Note: If your inpatient pharmacy needs Adempas and is not certified in the Adempas REMS, contact the Adempas REMS Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672) for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment.</p>			
REQUIRED	Authorized Representative Signature*:		Date* (MM/DD/YYYY):

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact: Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.



Phone: 1-855-4ADEMPAS (1-855-423-3672)

www.adempasREMS.com

Fax: 1-855-662-5200

ADEMPAS[®] REMS (RISK EVALUATION AND MITIGATION STRATEGY)



Prescriber and Pharmacy Guide for the Adempas REMS

Changes to the Adempas Risk Evaluation and Mitigation Strategy (REMS) February 2020

- Revised Form: Adempas REMS Patient and Enrollment and Consent Form
- Revised Form: Adempas REMS Prescriber Enrollment and Agreement Form

Table of Contents

I. Adempas REMS.....	3
II. Overview of the Adempas REMS.....	4
III. Summary of Adempas REMS Requirements by Patient Category.....	5
IV. Prescriber’s Role in the Adempas REMS.....	6
V. Contraceptive Options for Females of Reproductive Potential.....	8
VI. Role of Certified Pharmacies.....	9
VII. The Adempas REMS Coordinating Center.....	11



I. Adempas REMS (Risk Evaluation and Mitigation Strategy)

INDICATIONS

Adempas® (riociguat) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with:

- Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening.

Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).

RISK OF EMBRYO-FETAL TOXICITY

Adempas is contraindicated in females who are pregnant. Adempas may cause fetal harm when administered to a pregnant woman. Adempas was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. To prevent pregnancy, females of reproductive potential must use effective contraception during treatment and for one month after stopping Adempas. Patients must not become pregnant while taking Adempas.

ADEMPAS REMS

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug and is required by the US Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

Bayer Pharmaceuticals has worked with the FDA to develop the Adempas REMS to educate prescribers about the risk of embryo-fetal toxicity. The REMS requires that females be enrolled in the Adempas REMS in order to receive Adempas.

The goal of the Adempas REMS is to mitigate the risk of embryo-fetal toxicity associated with Adempas by:

1. Ensuring prescribers are educated on the following:

- the risks of embryo-fetal toxicity

2. Ensuring prescribers are educated on and adhere to the following:

- counseling patients about these risks and the need for monthly monitoring
- enrolling patients in the Adempas REMS
- monitoring patients at baseline and monthly

3. Ensuring that pharmacies are educated on the following:

- the risks of embryo-fetal toxicity

4. Ensuring that pharmacies are educated on and adhere to the following:

- confirming that the appropriate patient monitoring and counseling has occurred before dispensing Adempas

5. Ensuring that patients are informed about:

- the risks of embryo-fetal toxicity
- appropriate baseline and monthly patient monitoring
- appropriate contraception

II. Overview of the Adempas REMS

Because of the risk of embryo-fetal toxicity, Adempas is available only through the Adempas REMS, which includes restricted distribution of Adempas.

Therequired components of the Adempas REMS are:

- Healthcare providers (prescribers) who prescribe Adempas must:
 - enroll in the program, and comply with the REMS requirements
 - educate and counsel Females of Reproductive Potential on the risks of Adempas, including the risk of serious birth defects
 - order and review pregnancy tests for Females of Reproductive Potential before the start of treatment, monthly during treatment, and for one month after stopping treatment
 - report any change or misclassification in a female's reproductive status to the Adempas REMS
- Healthcare providers must enroll all female patients in the Adempas REMS after determining whether she is a Female of Reproductive Potential or a Female of Non-Reproductive Potential.

Definitions of Reproductive Potential Status

Females of Reproductive Potential

- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential
 - Post-Menopausal Females: Females who have passed through menopause. Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.
 - Females with other medical reasons for permanent, irreversible infertility.
- For Females of Reproductive Potential
 - pregnancy must be ruled out before the start of treatment, monthly during treatment, and one month after stopping treatment
 - she must agree to be contacted by Bayer if she becomes pregnant either while on Adempas or within one month of treatment discontinuation
 - Only certified outpatient pharmacies that agree to follow the Adempas REMS requirements via contract will dispense Adempas to outpatients.
 - Only certified inpatient pharmacies that agree to follow the Adempas REMS requirements will stock Adempas for inpatient use.
 - Only certified prescribers dispensing Adempas that agree to follow the Adempas REMS requirements will be eligible to obtain and dispense Adempas to patients. New and existing prescribers who wish to dispense Adempas must agree to these requirements by completing and signing the **Prescriber Enrollment and Agreement Form**.

III. Summary of the Adempas REMS

All prescribers must be enrolled in the Adempas REMS. To become enrolled, a healthcare provider must complete an *Prescriber Enrollment and Agreement Form* to the Adempas REMS agreeing to follow the Adempas REMS requirements. This form must be submitted to the Adempas REMS.

All females must be enrolled in the Adempas REMS in order to receive Adempas. To become enrolled a patient must complete an *Patient Enrollment and Consent Form* with her prescriber. This form must be submitted to the Adempas REMS.

Prescribers must determine and document on the *Patient Enrollment and Consent Form* whether the patient is a Female of Reproductive Potential, or a Female of Non-Reproductive Potential (Pre-Pubertal Female, Post-Menopausal Female, or a female with other medical reasons for permanent, irreversible infertility). **This category must be documented on the *Patient Enrollment and Consent Form*.** (See Section II for definitions of Reproductive Potential Status).

Based on whether the patient is a Female of Reproductive Potential, a Pre-Pubertal Female, a Post-Menopausal Female, or a female with other medical reasons for permanent, irreversible infertility, the prescriber must perform certain actions before initiating treatment, during treatment, and after the patient stops taking Adempas.

Summary of Adempas REMS Requirements by Patient Category

Requirement	Female of Reproductive Potential	Female of Non-Reproductive Potential		
		Pre-Pubertal	Post-Menopausal	Other medical reasons for permanent, irreversible infertility
Prescriber enrolls female patients into the Adempas REMS	X	X	X	X
Counseling with the <i>Guide for Female Patients</i>	X	X*		
Prescriber must order and review pregnancy tests before the start of treatment, monthly during treatment, and for one month after stopping treatment	X			
Prescriber must verify reproductive status annually by completing the <i>Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form</i> for females who are at least 8 years of age and older		X		
Prescriber must complete the <i>Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form</i> upon becoming aware of any change or misclassification in reproductive status within 10 business days of awareness	X	X	X	X

*Counsel Pre-Pubertal Female patient and/or a parent/guardian

IV. Prescriber's Role in the Adempas

Prescribers must complete the following steps in the Adempas REMS:

1. Enroll in the Adempas REMS

- Prior to writing an Adempas prescription for a patient, a healthcare provider must enroll in the Adempas REMS.
 - **Read** the *Adempas Prescribing Information (PI)* and the *Prescriber and Pharmacy Guide* (this guide) to understand the risks of Adempas and the Adempas REMS requirements.
 - **Agree** to follow the Adempas REMS requirements by completing and submitting an *Prescriber Enrollment and Agreement Form* to the Adempas REMS.
 - **Receive** an enrollment confirmation from the Adempas REMS verifying that certification has been completed. Prescribers can access the program materials at www.AdempasREMS.com.

2. Determine the Reproductive Status of Female Patients

(See definitions in Section II: Overview of the Adempas REMS).

3. Educate and Counsel Patients

- For all females, prescribers must:
 - Advise the patient that Adempas is only available through a restricted distribution program called the Adempas REMS.
 - Assess the patient's reproductive status using the definitions in the *Prescriber and Pharmacy Guide*. Document and submit the results to the REMS using the Patient Enrollment Form
- For Females of Reproductive Potential, prescribers must:
 - Review with her the *Guide for Female Patients*.
 - Counsel the patient on the risk of embryo-fetal toxicity, the need to use effective contraception

during treatment and for one month following treatment discontinuation, her medical options in the event of unprotected sexual intercourse or known or suspected contraception failure, and to immediately contact her healthcare provider if she misses a menstrual period or suspects that she is pregnant using the *Guide for Female Patients*.

- Advise the patient of the requirement for initial and monthly pregnancy tests to confirm they are not pregnant, so they can begin and continue to receive Adempas.
 - Counsel the patient if she is not complying with the required testing or if she is not using effective contraception.
 - Counsel her to immediately contact her healthcare provider if she misses a menstrual period or suspects she is pregnant.
- For Females of Non-Reproductive Potential
 - For a Post-Menopausal Female or a female with other medical reasons for permanent, irreversible infertility, prescribers must:
 - Provide the *Guide for Female Patients* and instruct her to read it.
 - For Pre-Pubertal Females, prescribers must:
 - Review with her and a parent/guardian the *Guide for Female Patients*.
 - Counsel her and a parent/guardian about the risk of embryo-fetal toxicity.
 - Counsel her and a parent/guardian to immediately contact her healthcare provider if she gets her menstrual period.
 - Prescribers must counsel any patient who fails to comply with the program requirements.

4. Check Pregnancy Status (in Females of Reproductive Potential)

- Order a pregnancy test.
- Review the pregnancy test results before the start of treatment with Adempas to ensure the result is negative.
- Notify the patient of negative pregnancy test results prior to the initiation of Adempas.

5. Enroll Female Patients in the Adempas REMS

- All female patients must be enrolled in the Adempas REMS in order to receive Adempas.
- Confirm that the patient has agreed to comply with the Adempas REMS requirements.
- Complete with the patient the designated sections of the *Patient Enrollment and Consent Form* and submit it to the Adempas REMS.

6. Monitor Patients

- For Females of Reproductive Potential, prescribers must:
 - Order and review pregnancy tests monthly during treatment with Adempas and for one month after stopping treatment.
 - Notify the patient and Bayer if a patient's pregnancy test is positive.
 - Monitor patients' reproductive status during treatment with Adempas and report any changes or misclassifications to the Adempas REMS by completing and submitting the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form* within 10 business days of becoming aware of the change.


- For Females of Non-Reproductive Potential, prescribers must:
 - Monitor patients' reproductive status during treatment with Adempas and report any changes or misclassifications to the Adempas REMS by completing and submitting the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form* within 10 business days of becoming aware of the change.
 - For each Pre-Pubertal Female who is at least 8 years of age and older, annually verify and report the reproductive status by completing and submitting the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form*.

7. Report Pregnancies

- Prescribers must also report as soon as possible any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

V. Contraceptive Options for Females of Reproductive Potential

Females of Reproductive Potential must use effective contraception during treatment and for one month after stopping treatment. The table below indicates the acceptable contraception methods. The patient should be instructed to select one of the below options.



All Females of Reproductive Potential should undergo contraceptive counseling with either the prescriber or another designated healthcare provider trained in contraceptive counseling. Counseling should include a discussion about medical options in the event of unprotected sex or known or suspected contraceptive failure.

If pregnancy is suspected for any reason, a pregnancy test must be performed. The prescriber must notify the Adempas REMS of any pregnancies that occur during treatment or within one month after stopping treatment as soon as possible.

VI. Role of Certified Pharmacies

Outpatient Pharmacy Dispensing:

Only a limited number of certified pharmacies will dispense Adempas for outpatients. Prior to dispensing Adempas to any female, the pharmacy will confirm that the female and the prescriber who wrote the prescription are enrolled in the Adempas REMS. If either the female or prescriber is not enrolled, Adempas will not be dispensed.

For all female patients, outpatient pharmacies will:

- Contact the Adempas REMS Coordinating Center to determine if the patient has received medication from the prescriber.
- Verify the female patient is enrolled, the reproductive status has not changed, the prescriber is certified, and if the prescriber dispensed a 30 days' supply of Adempas through processes and procedures established as a requirement of the REMS.

For Females of Reproductive Potential, outpatient pharmacies will:

- Counsel her on the risk of embryo-fetal toxicity
- Contact her each month to arrange the dispensing of Adempas
- Ask if she has had a pregnancy test within the last month or the prescriber has authorized the refill
- Counsel her on the need to use effective contraception during Adempas treatment and for one month after stopping treatment
- Counsel her to get monthly pregnancy tests
- Counsel her to inform her prescriber immediately if she misses a menstrual period or suspects that she may be pregnant
- Verify reproductive status has not changed
- Dispense no more than a 30-days' supply

All outpatient pharmacists must report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

Females of Reproductive Potential will only be able to get a 30-day supply of Adempas at one time.

Inpatient Pharmacy Dispensing:

Only inpatient pharmacies within institutions such as hospitals, long-term care facilities, and prisons that are certified in the Adempas REMS may stock Adempas for patients being treated in the inpatient setting.

As a certified inpatient pharmacy, you must agree to follow the Adempas REMS requirements including:

1. Become certified in the Adempas REMS

- Prior to stocking and dispensing Adempas, an authorized representative from the inpatient pharmacy must enroll and be certified in the Adempas REMS by completing and submitting an *Inpatient Pharmacy Enrollment Form* to the Adempas REMS, agreeing to meet all of the steps and requirements outlined in the enrollment form.
 - Bayer may require re-certification of inpatient pharmacies if there are substantive changes to the Adempas REMS.

2. Ensure Adempas REMS requirements are met

- establish processes and procedures to ensure Adempas REMS requirements are met
- maintain records that all processes and procedures are in place and are being followed
- complete training in the Adempas REMS by reading the *Prescriber and Pharmacy Guide* (this guide)
- assume responsibility for the training of all relevant staff in dispensing Adempas REMS requirements, procedures, and Adempas REMS materials prior to dispensing Adempas, using the *Prescriber and Pharmacy Guide*
- establish processes and procedures to verify the female patient is enrolled in the REMS or will be enrolled prior to discharge, her reproductive status, and the female patient is under the supervision and care of a certified prescriber
- for females of reproductive potential: establish processes and procedures to verify pregnancy testing is complete and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately

3. Confirm Inpatient and Prescriber Enrollment in the Adempas REMS

- verify the female patient is under the supervision and care of a certified prescriber, her reproductive status, and that she is enrolled or will be enrolled in the REMS prior to discharge through the processes and procedures established as a requirement of the REMS.
- for females of reproductive potential: Verify pregnancy testing is complete, and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately through the processes and procedures established as a requirement of the REMS.
- at discharge, verify female patient is enrolled in the REMS through the processes and procedures established as a requirement of the REMS

4. Comply with Dispensing Requirements

- do not distribute, transfer, loan, or sell Adempas
- comply with audits by the manufacturer or a third party acting on behalf of the manufacturer to ensure all processes and procedures are in place and being followed
- dispense no more than a 15-day temporary supply of Adempas to any female patient upon discharge from the healthcare facility

5. Report Pregnancies

- All inpatient pharmacists must report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

6. Purchase Adempas through Specialty Distributors

- Certified inpatient pharmacies will only be able to purchase Adempas through a limited number of specialty distributors contracted with Bayer.





Adempas[®] REMS (Risk Evaluation and Mitigation Strategy) Guide for Female Patients

Table of Contents

I. What is Adempas?.....	3
II. What are the serious risks of Adempas?	3
III. What is the Adempas REMS?	3
IV. How do I enroll in the Adempas REMS?.....	3
V. What are the Adempas REMS requirements for me?.....	4
VI. What are my birth control options?.....	5
VII. How will I get my Adempas medicine?	6
VIII. Where can I look for more information about Adempas or the Adempas REMS?	6



I. What is Adempas (riociguat)?

Adempas® is a prescription medicine used to treat adults with:

- **chronic thromboembolic pulmonary hypertension (CTEPH)**
 - treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or
 - that cannot be treated with surgery

CTEPH is a type of high blood pressure in the arteries of your lungs caused by blood clots that narrow or block blood flow. Adempas can improve your ability to exercise and can help to improve some of your symptoms.

- **pulmonary arterial hypertension (PAH)**

PAH is a type of high blood pressure in the arteries of your lungs. Adempas can improve your ability to exercise, improve some of your symptoms, and help slow down the worsening of your physical condition.

It is unknown if Adempas is safe and effective in children.

II. What are the serious risks of Adempas?

Adempas may cause serious birth defects if taken while you are pregnant. You must not be pregnant when you start to take Adempas, become pregnant while taking Adempas, or become pregnant for one month after stopping Adempas.

III. What is the Adempas REMS (Risk Evaluation and Mitigation Strategy)?

The Adempas REMS is a program to tell patients and healthcare providers about the serious risks of birth defects while taking Adempas. This program is required by the Food and Drug Administration (FDA). All females must enroll in the Adempas REMS to receive Adempas. REMS stands for Risk Evaluation and Mitigation Strategy.

IV. How do I enroll in the Adempas REMS?

- Talk with your healthcare provider to make sure that Adempas is right for you
- Read the *Guide for Female Patients* (this guide)
- Ask your healthcare provider any questions that you have about Adempas and the Adempas REMS
- Agree to all the requirements of the Adempas REMS
- Complete and sign the *Patient Enrollment and Consent Form* with your healthcare provider

To enroll you in the Adempas REMS, your healthcare provider will send in your *Patient Enrollment and Consent Form*. The Adempas REMS will keep your information in a secure and validated database.

V. What are the Adempas REMS requirements for me?

Females Who Cannot Get Pregnant:

You are considered a female who **cannot** get pregnant if you have not yet entered puberty, **or** you do not have a uterus, **or** you have gone through menopause (have not had a period for at least 12 months for natural reasons, or have had your ovaries removed)

To receive Adempas, you must:

- Receive counseling from your prescriber on the risk of serious birth defects (Pre-menopausal only)
- Tell your prescriber if your ability to become pregnant changes
- If you are over the age of 8: Be monitored to see if your ability to become pregnant changes **and** immediately contact your prescriber if you begin to menstruate.

If you are the parent or caregiver of a female child who started taking Adempas before reaching puberty, you should check your child regularly to see if she is developing signs of puberty. Tell your doctor right away if you notice that she is developing breast buds or pubic hair. Your doctor should decide if your child has reached puberty. **Your child may reach puberty before having her first menstrual period.**

Females Who Can Get Pregnant:

You are considered a female who is able to get pregnant if you:

- have entered puberty, even if you have not started your period, and
- have a uterus, **and**
- have not gone through menopause (have not had a period for at least 12 months for natural reasons, or you have had your ovaries removed)


If you are a female who can get pregnant, to receive Adempas you must:

- Receive counseling from your prescriber on the risks and benefits of Adempas
- Make sure you understand the risks and benefits of taking Adempas

- Have a pregnancy test before you start taking Adempas to be sure you are not pregnant
- Have a pregnancy test before you receive your refill each month
 - o Your healthcare provider will order the pregnancy tests for you
 - o Your pharmacy will call you every month to:
 - ask if you have taken a pregnancy test in the last month
 - remind you to use effective birth control
 - o Be sure you take your monthly pregnancy tests as ordered by your healthcare provider. You may not receive your Adempas refill on time if you do not take your monthly pregnancy tests
- Use effective forms of birth control during Adempas treatment and for one month after stopping treatment with Adempas
 - o Do not have unprotected sex.
 - o Use the birth control options described on page 4 of this guide during your Adempas treatment and for one month after stopping your Adempas treatment.
 - o Talk to your healthcare provider or pharmacist right away if you have unprotected sex, if you think your birth control has failed, or if you think you may be pregnant. If so, your healthcare provider may discuss medical options with you (e.g. emergency contraception). Do not wait until your next appointment to tell your healthcare provider if you miss your menstrual period or if you think you may be pregnant.
- **Immediately notify your healthcare provider if you miss a menstrual period or suspect you are pregnant.**
- Talk to your healthcare provider if you have any questions about being a female who is able to get pregnant or about taking Adempas.

VI. What are my birth control options?

If you are a female who can get pregnant, your healthcare provider will talk to you about your options for effective birth control. Use the tables below to help decide what birth control option is best for you.



If you can get pregnant, do not have unprotected sex. Talk to your healthcare provider or pharmacist right away if you have unprotected sex or if you think your birth control has failed. If so, your healthcare provider may discuss medical options with you (e.g. emergency contraception). Tell your healthcare provider right away if you miss a menstrual period or if you think you may be pregnant.

VII. How will I get my Adempas medicine?

Adempas is not available at your local pharmacy. You can only get it through a certified pharmacy, sometimes called a "specialty pharmacy". After you enroll, your prescription will be sent to a certified pharmacy.

Before the pharmacy sends your prescription, they will call to confirm that you had a pregnancy test taken in the last month if you are a female who can get pregnant.

The pharmacy will send Adempas directly to your home or where you tell them to send it.

- If you did not complete your pregnancy test for that month, your Adempas prescription or refill will be delayed.
- The pharmacy will remind you to use effective birth control during treatment with Adempas and for one month after stopping treatment with Adempas.

The pharmacy will also:

- Handle your insurance claims
- Answer questions that you have about Adempas

VIII. Where can I find more information about Adempas and the Adempas REMS?

- Talk with your healthcare provider, nurse, or pharmacist about Adempas.
- For questions about getting your Adempas prescription filled or being in the Adempas REMS, please call the Adempas REMS Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672).

*You may also receive a 30-day supply of Adempas from your doctor when you first start taking Adempas.



Adempas REMS (Risk Evaluation and Mitigation Strategy)

Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form

All females must be enrolled in the Adempas REMS in order to receive Adempas.

Complete this form to:

- 1) Change the reproductive status of any female patient, or
- 2) Perform the annual verification of reproductive status for Pre-Pubertal Females, 8 years of age or older

Access this form online at www.adempasREMS.com or fax this form to the Adempas REMS at 1-855-662-5200 and to the patient's certified pharmacy.

Prescriber must complete this form within 10 business days of awareness of the change in reproductive status.

Patient Information (* indicates required field)

First Name*:	Middle Initial:	Last Name*:	Birthdate*(MM/DD/YYYY):
Address Line 1*:		Address Line 2:	
City*:	State*:	Zip code*:	Phone:

Prescriber Information (* indicates required field)

First Name*:	Last Name*:	NPI*:	
Practice/Facility Name:			
Address Line 1*:		Address Line 2:	
City:	State:	Zip code:	Phone*:

Definitions of Reproductive Potential Status

Females of Reproductive Potential

- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Females: Females who have passed through menopause. Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.
- Females with other medical reasons for permanent, irreversible infertility.

Please select the most appropriate reason for submitting this form*:

Change in Status

• **Based on definitions of reproductive potential status, patient is (please check one):**

- Female of Reproductive Potential
- Female of Non-Reproductive Potential – Patient is pre-pubertal
- Female of Non-Reproductive Potential – Patient is post-menopausal
- Female of Non-Reproductive Potential – Female with other medical reasons for permanent, irreversible infertility

• **Reason for change in classification (please check one):**

- Physiological transition
- Medical/surgical (please specify): _____
- Other (please specify): _____

Annual Verification

- Patient remains a Pre-Pubertal Female (8 years of age or older)

By signing, I certify that the patient's reproductive potential status and reason for submitting this form are accurately noted above. I certify that I will follow the REMS requirements while treating this patient.

REQUIRED	Prescriber Signature*:	Date* (MM/DD/YYYY):
-----------------	------------------------	---------------------

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact: Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.



Phone: 1-855-4ADEMPAS (1-855-423-3672)

www.adempasREMS.com

Fax: 1-855-662-5200

Welcome to the Adempas REMS (Risk Evaluation and Mitigation Strategy)

The Adempas REMS is a program to tell patients and healthcare providers about the serious risks of birth defects while taking Adempas. This program is required by the Food and Drug Administration (FDA). All females must enroll in the Adempas REMS to receive Adempas. REMS stands for Risk Evaluation and Mitigation Strategy.

Bayer Pharmaceuticals has worked with the FDA to develop the Adempas REMS to educate prescribers and patients about the risk of embryo-fetal toxicity. The REMS will require that females agree to follow the REMS requirements to be enrolled in the Adempas REMS in order to receive Adempas® (riociguat).

Adempas REMS Overview

- Females must not be pregnant when they start taking Adempas, become pregnant during treatment, or become pregnant for one month after stopping Adempas treatment.
- All healthcare providers must enroll in the Adempas REMS and agree to the REMS requirements to prescribe Adempas.
- All female patients must enroll in the Adempas REMS and agree to the REMS requirements to receive Adempas.
- A limited number of certified pharmacies will dispense Adempas for outpatients. They must enroll in the Adempas REMS and agree to the REMS requirements to provide Adempas for outpatient use.
- Inpatient pharmacies must enroll in the Adempas REMS and agree to the REMS requirements to stock Adempas for inpatient use.

Changes to the Adempas Risk Evaluation and Mitigation Strategy (REMS) February 2020

- Revised Form: [Adempas REMS Patient Enrollment and Consent Form](#)
- Revised Form: [Adempas REMS Prescriber Enrollment and Agreement Form](#)

Click below to learn more about the Adempas REMS



To learn more about the serious risks associated with Adempas, please refer to the *Prescribing Information* including Boxed Warning, *Spanish Prescribing Information*, *Adempas Medication Guide*, *Spanish Adempas Medication Guide*, *Prescriber and Pharmacy Guide*, *Guide for Female Patients* and the *Spanish Guide for Female Patients*.

INDICATIONS

- Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
- Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class, and to delay clinical worsening.

Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. BAYER, the Bayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

PRESCRIBER OVERVIEW

Due to the risk of embryo-fetal toxicity, Adempas is available only through the Adempas REMS (Risk Evaluation and Mitigation Strategy).

The goal of the Adempas REMS is to mitigate the risk of embryo-fetal toxicity associated with Adempas by:

1. Ensuring prescribers are educated on the following:
 - the risks of embryo-fetal toxicity
2. Ensuring prescribers are educated on and adhere to the following:
 - counseling patients about these risks and the need for monthly monitoring
 - enrolling patients in the ADEMPAS REMS
 - monitoring patients at baseline and monthly
3. Ensuring that pharmacies are educated on the following:
 - the risks of embryo-fetal toxicity
4. Ensuring that pharmacies are educated on and adhere to the following:
 - confirming that the appropriate patient monitoring and counseling has occurred before dispensing Adempas
5. Ensuring that patients are informed about:
 - the risks of embryo-fetal toxicity
 - appropriate baseline and monthly patient monitoring
 - appropriate contraception

In order to prescribe and receive Adempas, prescribers and females must enroll in the Adempas REMS and agree to comply with the requirements of the program.

Only a limited number of certified pharmacies will dispense Adempas to outpatients.

To enroll in the Adempas REMS, prescribers must:

- Read the Adempas [Prescribing Information \(PI\)](#) and the [Prescriber and Pharmacy Guide](#)
- Agree to follow the REMS requirements by completing and submitting a [Prescriber Enrollment and Agreement Form](#)
- Complete and submit the [Prescriber Enrollment and Agreement Form](#):
 - [Online](#)
 - [By fax](#) at 1-855-662-5200
 - [By calling the Adempas REMS](#) at 1-855-4ADEMPAS (1-855-423-3672)
- Receive an enrollment confirmation from the Adempas REMS verifying that enrollment has been completed

[Prescriber Roles & Responsibilities](#)

PDFs for Download

Materials for Healthcare Providers

-  [Prescriber and Pharmacy Guide for the Adempas REMS](#)
-  [Adempas REMS Prescriber Enrollment and Agreement Form](#)
-  [Adempas REMS Patient Enrollment and Consent Form](#)
-  [Spanish Adempas REMS Patient Enrollment and Consent Form](#)
-  [Adempas REMS Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form](#)
-  [Adempas REMS Inpatient Pharmacy Enrollment Form](#)

Materials for Patients

-  [Adempas REMS Guide for Female Patients](#)
-  [Spanish Adempas REMS Guide for Female Patients](#)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. BAYER, the Bayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

PRESCRIBER ROLES AND RESPONSIBILITIES

1. Enroll in the Adempas REMS

- Prior to writing an Adempas prescription for a patient, a healthcare provider must enroll in the Adempas REMS.
 - **Read** the Adempas *Prescribing Information (PI)* and the *Prescriber and Pharmacy Guide* to understand the risks of Adempas and the Adempas REMS requirements.
 - **Agree** to follow the Adempas REMS requirements by completing and submitting a *Prescriber Enrollment and Agreement Form*
 - Complete and submit the *Prescriber Enrollment and Agreement Form*:
 - [Online](#)
 - [By fax at 1-855-662-5200](#)
 - [By calling the Adempas REMS at 1-855-4ADEMPAS \(1-855-423-3672\)](#)
 - **Receive** an enrollment confirmation from the Adempas REMS verifying that enrollment has been completed.

2. Determine the reproductive potential status of female patients

Females of Reproductive Potential

- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Females: Females who have passed through menopause. Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.
- Females with other medical reasons for permanent, irreversible infertility.

3. Educate and Counsel Patients

- For all females, prescribers must:
 - Advise the patient that Adempas is only available through a restricted distribution program called the Adempas REMS.
 - Assess the patient's reproductive status using the definitions in the *Prescriber and Pharmacy Guide*. Document and submit the results to the REMS using the *Patient Enrollment and Consent Form*.
- For Females of Reproductive Potential, prescribers must:
 - Review with her the *Guide for Female Patients*.
 - Counsel the patient on the risk of embryo-fetal toxicity, the need to use effective contraception during Adempas treatment and for one month following treatment discontinuation, and the need to consider medical options in the event of unprotected sexual intercourse or known or suspected contraception failure, and to immediately contact her healthcare provider if she misses a menstrual period or suspects that she is pregnant using the *Guide for Female Patients*.
 - Advise the patient of the requirement for initial and monthly pregnancy tests to confirm they are not pregnant, so they can begin and continue to receive Adempas.
 - Counsel the patient if she is not complying with the required testing or if she is not using effective contraception.
 - Counsel her to immediately contact her healthcare provider if she misses a menstrual period or suspects she is pregnant.
- For Females of Non-Reproductive Potential
 - For a Post-Menopausal Female or a female with other medical reasons for permanent, irreversible infertility prescribers must:
 - Provide the *Guide for Female Patients* and instruct her to read it.
 - For Pre-Pubertal Females, prescribers must:
 - Review with her and her parent/guardian the *Guide for Female Patients*.
 - Counsel her and her parent/guardian about the risk of embryo-fetal toxicity.
 - Counsel her and her parent/guardian to immediately contact her healthcare provider if she gets her menstrual period.
- Prescribers must counsel any patient who fails to comply with the program requirements.

4. Check Pregnancy Status (in Females of Reproductive Potential)

- Order a pregnancy test.
- Review the pregnancy test results prior to the initiation of Adempas to ensure the result is negative.
- Notify the patient of negative pregnancy test results prior to the initiation of Adempas.

5. Enroll Female Patients in the Adempas REMS

- All female patients must be enrolled in the Adempas REMS in order to receive Adempas.
- Confirm that the patient has agreed to comply with the Adempas REMS requirements.
 - Complete with the patient the designated section of the *Patient Enrollment and Consent Form* and submit it to the Adempas REMS.
 - Prescribers can complete the *Patient Enrollment and Consent Form*:
 - [Online](#)
 - [By fax at 1-855-662-5200](#)

6. Monitor Patients

- For Females of Reproductive Potential, prescribers must:
 - Order and review pregnancy tests monthly during treatment with Adempas and for one month after stopping treatment.
 - Notify the patient and Bayer if a patient's pregnancy test is positive.
 - Monitor patients' reproductive status during treatment with Adempas and report any changes or misclassifications to the Adempas REMS by completing and submitting the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form* within 10 business days of becoming aware of the change.
- For Females of Non-Reproductive Potential and Pre-Pubertal Females, prescribers must:
 - Monitor patients' reproductive status during treatment with Adempas and report any changes or misclassifications to the Adempas REMS by completing and submitting the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form* within 10 business days of becoming aware of the change.
 - Prescribers can complete the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form*:
 - [Online](#)
 - [By fax at 1-855-662-5200](#)
 - For each Pre-Pubertal Female who is at least 8 years of age and older, annually verify and report the reproductive status by completing and submitting the *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form*.

7. Report Pregnancies

- Prescribers must also report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

PDFs for Download

Materials for Healthcare Providers

-  [Prescriber and Pharmacy Guide for the Adempas REMS](#)
-  [Adempas REMS Prescriber Enrollment and Agreement Form](#)
-  [Adempas REMS Patient Enrollment and Consent Form](#)
-  [Spanish Adempas REMS Patient Enrollment and Consent Form](#)
-  [Adempas REMS Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form](#)
-  [Adempas REMS Inpatient Pharmacy Enrollment Form](#)

Materials for Patients

-  [Adempas REMS Guide for Female Patients](#)
-  [Spanish Adempas REMS Guide for Female Patients](#)

INFORMATION FOR FEMALE PATIENTS

Adempas[®] is a prescription medicine to treat adults with:

- **chronic thromboembolic pulmonary hypertension (CTEPH)**
 - treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), **or**
 - that cannot be treated with surgery

CTEPH is a type of high blood pressure in the arteries of your lungs caused by blood clots that narrow or block blood flow. Adempas can improve your ability to exercise and can help to improve some of your symptoms.

- **pulmonary arterial hypertension (PAH)**

PAH is a type of high blood pressure in the arteries of your lungs. Adempas can improve your ability to exercise, improve some of your symptoms, and help slow down the worsening of your physical condition.

It is unknown if Adempas is safe and effective in children.

Because of the serious risks of birth defects while taking Adempas, the FDA (Food and Drug Administration) requires a program called REMS. REMS stands for **R**isk **E**valuation and **M**itigation **S**trategy. The purpose of this program is to make sure that patients and prescribers understand the risks. All females must enroll in the Adempas REMS to receive Adempas.

Females Who Cannot Get Pregnant:

You are considered a female who cannot get pregnant if you have not yet entered puberty, or you do not have a uterus, or you have gone through menopause (have not had a period for at least 12 months for natural reasons, or have had your ovaries removed).

To receive Adempas, you must:

- Enroll in the Adempas REMS by completing the **Patient Enrollment and Consent Form**.
- Receive counseling from your prescriber on the risk of serious birth defects (Pre-menopausal only)
- Tell your prescriber if you become pregnant or your ability to become pregnant changes
- If you are over the age of 8: Be monitored every year to see if your ability to become pregnant changes and tell your prescriber if your ability to become pregnant changes

If you are the parent or caregiver of a female child who started taking Adempas before reaching puberty, you should check your child regularly to see if she is developing signs of puberty. Tell your doctor right away if you notice that she is developing breast buds or pubic hair. Your doctor should decide if your child has reached puberty. **Your child may reach puberty before having her first menstrual period.**

Females Who Can Get Pregnant:

You are considered a female who is able to get pregnant if you have entered puberty, even if you have not started your period, and you have a uterus, and have not gone through menopause (have not had a period for at least 12 months for natural reasons or you have had your ovaries removed).

If you are a female who can get pregnant, to receive Adempas you must:

- Talk to your healthcare provider about the risks and benefits of Adempas.
- Read:
 - The [Guide for Female Patients](#), [Spanish Guide for Female Patients](#)
- Make sure you understand the risks and benefits of taking Adempas
- Have a pregnancy test before you start taking Adempas to be sure you are not pregnant
- Have a pregnancy test before you receive your refill each month
- Use effective forms of birth control during Adempas treatment and for one month after stopping treatment with Adempas
- Immediately notify your healthcare provider if you miss a menstrual period or suspect you are pregnant

For more information on Adempas, the Adempas REMS and effective forms of birth control, download the [Guide for Female Patients](#), [Spanish Guide for Female Patients](#).

To learn more about the serious risks associated with Adempas, please refer to the [Prescribing Information](#) including Boxed Warning, [Spanish Prescribing Information](#).

PDFs for Download

Materials for Patients

-  [Adempas REMS Guide for Female Patients](#)
-  [Spanish Adempas REMS Guide for Female Patients](#)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit: www.fda.gov/medwatch, or call 1-800-FDA-1088. BAYER, the Dayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

CERTIFIED OUTPATIENT PHARMACY OVERVIEW

Due to the risk of embryo-fetal toxicity, Adempas is available only through the Adempas REMS.

Adempas will be dispensed to outpatients by a limited number of certified pharmacies. Prior to dispensing Adempas the pharmacy will confirm that the prescriber who wrote the prescription is enrolled, and if the patient is a female that she is enrolled in the Adempas REMS. If either the female or prescriber is not enrolled, Adempas will not be dispensed.

For all female patients, outpatient pharmacies will:

- Contact the Adempas REMS Coordinating Center to determine if the patient has received sample medication from the prescriber
- Verify the female patient is enrolled, the reproductive status has not changed, and the prescriber is certified through processes and procedures established as a requirement of the REMS.

For Females of Reproductive Potential, outpatient pharmacies will:

- Counsel her on the risk of embryo-fetal toxicity
- Contact her each month to arrange the dispensing of Adempas
- Ask the patient if she has had a pregnancy test within the last month or that the prescriber has authorized the refill through processes and procedures established as part of the REMS requirements
- Counsel her on the need to use effective contraception during Adempas treatment and for one month after stopping treatment
- Counsel her to get monthly pregnancy tests
- Counsel her to inform her prescriber immediately if she misses a menstrual period or suspects that she may be pregnant
- Dispense no more than 30-days' supply

All outpatient pharmacists must report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com

Females of Reproductive Potential will only be able to get a 30-day supply of Adempas at one time.

To learn more about the serious risks associated with Adempas, please refer to the [Prescribing Information](#) including Boxed Warning, [Spanish Prescribing Information](#), and the [Prescriber and Pharmacy Guide](#).

PDFs for Download

Materials for Healthcare Providers

-  [Prescriber and Pharmacy Guide for the Adempas REMS](#)
-  [Adempas REMS Prescriber Enrollment and Agreement Form](#)
-  [Adempas REMS Patient Enrollment and Consent Form](#)
-  [Spanish Adempas REMS Patient Enrollment and Consent Form](#)
-  [Adempas REMS Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form](#)
-  [Adempas REMS Inpatient Pharmacy Enrollment Form](#)

Materials for Patients

-  [Adempas REMS Guide for Female Patients](#)
-  [Spanish Adempas REMS Guide for Female Patients](#)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. BAYER, the Bayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

CERTIFIED INPATIENT PHARMACY OVERVIEW

Due to the risk of embryo-fetal toxicity, Adempas is available only through the Adempas REMS.

In order to stock Adempas, inpatient pharmacies must enroll and be certified in the Adempas REMS.

Inpatient pharmacies must agree to follow the REMS requirements, including:

- Establish processes and procedures to ensure the REMS requirements are met.
- Complete training in the Adempas REMS by reading the *Prescriber and Pharmacy Guide*.
- Assign an authorized representative to assume responsibility for the training of dispensing staff on the Adempas REMS requirements and Adempas REMS materials prior to dispensing Adempas.
- Assume responsibility for the training of all relevant staff in dispensing on the Adempas REMS requirements, procedures, and Adempas REMS materials prior to dispensing Adempas, using the *Prescriber and Pharmacy Guide*.
- Establish processes and procedures to verify the female patient is enrolled in the REMS or will be enrolled prior to discharge, her reproductive status, and the female patient is under the supervision and care of a certified prescriber.
- For females of reproductive potential: establish processes and procedures to verify pregnancy testing is complete and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately.

Before dispensing:

- Verify the female patient is under the supervision and care of a certified prescriber, her reproductive status, and that she is enrolled or will be enrolled in the REMS prior to discharge through the processes and procedures established as a requirement of the REMS.
- For females of reproductive potential: Verify pregnancy testing is complete, and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately through the processes and procedures established as a requirement of the REMS.

At discharge:

- Verify the female patient is enrolled in the REMS through the processes and procedures established as a requirement of the REMS.
- Dispense no more than a 15-day temporary supply of Adempas to any female patient upon discharge from the healthcare facility.

At all times:

- Not distribute, transfer, loan, or sell Adempas.
- Report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.
- Comply with audits by the manufacturer or a third party acting on behalf of the manufacturer to ensure all processes and procedures are in place and being followed.
- Maintain records of all processes and procedures including compliance with those processes and procedures.

To be certified in the Adempas REMS, an authorized representative of the inpatient pharmacy must:

- Complete training in the Adempas REMS by reading the *Adempas Prescribing Information (PI)*, and the *Prescriber and Pharmacy Guide for the Adempas REMS* to understand the risks of Adempas and the Adempas REMS requirements.
- Agree to follow the REMS requirements by completing and submitting an *Inpatient Pharmacy Enrollment Form* to the Adempas REMS.
 - Authorized representatives can complete the *Inpatient Pharmacy Enrollment Form*:
 - [Online](#)
 - [By fax](#) at 1-855-662-5200
 - [By calling the Adempas REMS](#) at 1-855-4ADEMPAS (1-855-423-3672)
- If an inpatient pharmacy needs Adempas and is not certified in the Adempas REMS, the inpatient pharmacy can contact the Adempas REMS Program Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672) for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment.

To learn more about the serious risks associated with Adempas, please refer to the *Prescribing Information* including Boxed Warning, *Spanish Prescribing Information*, *Prescriber and Pharmacy Guide* and the *Guide for Female Patients*.

PDFs for Download

Materials for Healthcare Providers

-  [Prescriber and Pharmacy Guide for the Adempas REMS](#)
-  [Adempas REMS Prescriber Enrollment and Agreement Form](#)
-  [Adempas REMS Patient Enrollment and Consent Form](#)
-  [Spanish Adempas REMS Patient Enrollment and Consent Form](#)
-  [Adempas REMS Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form](#)
-  [Adempas REMS Inpatient Pharmacy Enrollment Form](#)

Materials for Patients

-  [Adempas REMS Guide for Female Patients](#)
-  [Spanish Adempas REMS Guide for Female Patients](#)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. BAYER, the Bayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

User Name:

Submit

Login is available for enrolled prescribers and office contacts designated by prescribers only.

To learn more about the serious risks associated with Adempas, please refer to the [Prescribing Information](#) including Boxed Warning, [Spanish Prescribing Information](#), and the [Prescriber and Pharmacy Guide](#).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
BAYER, the Bayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

Phone: 1-855-4ADEMPAS (1-855-423-3672)

Fax: 1-855-662-5200

Hours of Operation: Monday- Friday 8:00 AM - 8:00 PM Eastern

To report any adverse events, product technical complaints, medication errors, or pregnancies associated with the use of Adempas, contact:

Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

To learn more about the serious risks associated with Adempas, please refer to the [Prescribing Information](#) including Boxed Warning, [Spanish Prescribing Information](#), and the [Prescriber and Pharmacy Guide](#).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
BAYER, the Bayer Cross and ADEMPAS are registered trademarks of Bayer.

[Privacy Policy](#) [Conditions of Use](#) [Contact us](#) [California Transparency in Supply Chains](#)

This site is intended for US residents only.
Copyright © 2013 Bayer Pharmaceuticals, Inc. All rights reserved.
Version 1.7.0.42

Adempas REMS Patient Enrollment and Consent Form

1 Patient Information

* First Name:	Middle Initial:	* Last Name:
<input type="text"/>	<input type="text"/>	<input type="text"/>
* Address Line 1:	Address Line 2:	
<input type="text"/>	<input type="text"/>	
* City:	* State:	* Zip code:
<input type="text"/>	<input type="text" value="Please Select"/>	<input type="text"/>
* Birthdate:	* Gender:	
<input type="text"/>	<input type="radio"/> Male <input type="radio"/> Female	

Contact Information

* Preferred Phone:	Can we leave a message on this phone?:	Preferred Time to Contact:
<input type="text"/>	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Day <input type="radio"/> Evening
Cell/Alternate Phone:	* Email:	
<input type="text"/>	<input type="text"/>	

Alternate Contact Information

Alternate Contact Name:	Phone:	Relationship:
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="checkbox"/> 1 mg Adempas Sample Dispensed**	Date:	
	<input type="text"/>	
<input type="checkbox"/> 0.5 mg Adempas Sample Dispensed**	Date:	
	<input type="text"/>	

** Adempas Sample should only be dispensed as a 30-day supply.

2 Statement of Medical Necessity

The following does not suggest approved uses or indications.

- * Diagnosis:
- I27.0 Primary pulmonary hypertension I27.21 Secondary pulmonary hypertension I27.24 Chronic thromboembolic pulmonary hypertension (Inoperable)
 I27.24 Chronic thromboembolic pulmonary hypertension (Persistent/Recurrent) OTHER (please specify)

Therapy Status:

Initial Therapy (monotherapy or in combination) Add-on therapy Transition from other therapy

3 Female Patient Agreement

For all Females: I understand that Adempas is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).
For Females Who Can Get Pregnant: I have been counseled on the risks of Adempas, including the risk of serious birth defects. I have read the *Guide for Female Patients*. Before treatment initiation, I understand that I will receive counseling from the prescriber on: the risk of serious birth defects, the need to use effective contraception during Adempas treatment and for one month after stopping Adempas treatment, my medical options in the event of unprotected sexual intercourse or known or suspected contraception failure, and to immediately contact my prescriber if I miss a menstrual period or suspect that I am pregnant. Before each prescription, I will receive counseling by the pharmacy or the prescriber who dispenses Adempas on the risk of serious birth defects, the need to use effective contraception during Adempas treatment and for one month after stopping Adempas treatment, to get monthly pregnancy tests, and to report a pregnancy immediately. Ensure that I have completed pregnancy testing before I started Adempas, monthly before each refill, and for one month after stopping Adempas. I understand that I may be contacted by Bayer and/or its agents and contractors to obtain information about my pregnancy. I will communicate with the pharmacy to confirm completion of pregnancy testing.
For Pre-Pubertal Females: I have been counseled on the risks of Adempas, including the risk of serious birth defects, and that I have read the *Guide for Female Patients*. I understand that I must immediately contact my healthcare provider if I get my menstrual period.
For Post-Menopausal Females: I have received and read the *Guide for Female Patients* and that I will inform my prescriber if there is a change in my reproductive status.
For Females with other medical reasons for permanent, irreversible infertility: I have received and read the *Guide for Female Patients* and that I will inform my prescriber if there is a change in my reproductive status.

4 Prescriber Information

* First Name:	* Last Name:	* NPI Number:
<input type="text"/>	<input type="text"/>	<input type="text"/>
Practice/Facility Name:		
<input type="text"/>		
Address Line 1:	Address Line 2:	
<input type="text"/>	<input type="text"/>	
City:	State:	Zip code:
<input type="text"/>	<input type="text" value="-- Please Select --"/>	<input type="text"/>
Phone:	* Email:	State License #:
<input type="text"/>	<input type="text"/>	<input type="text"/>

5 Prescriber Authorization

For female patients, please indicate the patient's current reproductive status below.

- * Reproductive Status:
- Female of Reproductive Potential
 Female of Non-Reproductive Potential

I certify that the information provided is accurate to the best of my knowledge. I certify that for female patients, I have provided the appropriate counseling and Adempas REMS materials, and I will continue to fulfill my obligations under the Adempas REMS Program. I understand that I may not delegate signature authority.

Definitions:

Females of Reproductive Potential

- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Females: Females who have passed through menopause. Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or postsurgical from bilateral oophorectomy.
- Females with other medical reasons for permanent, irreversible infertility.

Prescriber Obligations under the Adempas REMS

For All Females, I will:

- determine the reproductive potential status of all female patients using the definitions provided in the *Prescriber and Pharmacy Guide*.
- advise all females that Adempas is only available through a restricted distribution program called the Adempas REMS.
- enroll all female patients into the Adempas REMS by completing the *Patient Enrollment and Consent Form* and submitting it to the REMS.

For Females of Reproductive Potential, I will:

- counsel Females of Reproductive Potential (FRP) on Adempas risks, including serious birth defects; and review the *Guide for Female Patients* with the patient.
- counsel each FRP to immediately contact her prescriber if she misses a menstrual period or suspects pregnancy.
- order and review pregnancy tests for FRPs before the start of treatment, monthly during treatment, and for one month after stopping treatment.
- counsel each FRP to use effective contraception during Adempas treatment and for one month after stopping treatment and discuss her medical options in the event of unprotected sexual intercourse or known or suspected contraceptive failure using the *Guide for Female Patients*.
- counsel each FRP during treatment if she is not complying with the required testing or if she is not using effective contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant.

For Pre-Pubertal Females, I will:

- counsel the Pre-Pubertal Female (PPF) patient on the Adempas risks, including serious birth defects and to immediately contact her prescriber if she begins to menstruate.
- Review the *Guide for Female Patients* with the patient.
- for PPF, regularly assess the reproductive status of each pre-pubertal female during their treatment with Adempas.

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact: Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Red Asterisk * - Required field for submitting enrollment form

CANCEL CONTINUE TO SIGN

5 Prescriber Authorization

For female patients, please indicate the patient's current reproductive status below.

* Reproductive Status:

- Female of Reproductive Potential
- Female of Non-Reproductive Potential

* If this patient is a Female of Reproductive Potential has a pregnancy test been completed prior to prescribing Adempas?:

- Yes
- No

I certify that the information provided is accurate to the best of my knowledge. I certify that for female patients, I have provided the appropriate counseling and Adempas REMS materials, and I will continue to fulfill my obligations under the Adempas REMS. I understand that I may not delegate signature authority.

Reference ID: 4709629

Definitions:

5 Prescriber Authorization

For female patients, please indicate the patient's current reproductive status below.

*** Reproductive Status:**

- Female of Reproductive Potential
- Female of Non-Reproductive Potential

*** Female of Non-Reproductive Potential:**

- Pre-Pubertal Female
- Post-Menopausal Female
- Female with other medical reasons for permanent, irreversible infertility

I certify that the information provided is accurate to the best of my knowledge. I certify that for female patients, I have provided the appropriate counseling and Adempas REMS materials, and I will continue to fulfill my obligations under the Adempas REMS. I understand that I may not delegate signature authority.

Reference ID: 4709629

Adempas REMS (Risk Evaluation and Mitigation Strategy) Program Prescriber Enrollment and Agreement Form

In order to prescribe Adempas, prescribers must enroll in the Adempas REMS by completing this form. In order to receive samples of Adempas, prescribers must be enrolled in the Adempas REMS and agree to comply with the requirements for a Sample Dispensing Prescriber, detailed in the agreement below.

Access this form online at www.adempasREMS.com, fax this form to 1-855-662-5200 or call the Adempas REMS Program at 1-855-4ADEMPAS (1-855-423-3672).

Prescriber Information (* indicates required field)

First Name: JOHN
 Middle Name:
 Last Name: SMITH

NPI: 1234567890
 State License #:

*Specialty: Cardiology
 Pulmonology
 Other

*Credentials: MD
 DO
 NP
 PA
 Other with prescriptive authority

Facility Name:
 *Address 1: 13795 KENWOOD DR
 Address 2:
 *City: BAXTER
 *State: MN
 *ZipCode: 56425-8504
 *Phone Number: 435-313-0686
 *Fax Number:
 *Email:

Preferred Method of Contact:

Phone Number:
 Email:
 Fax Number:

Office Contact

Primary Contact

First Name:
 Last Name:
 Email (Required if office contact is provided):

Secondary Contact

First Name:
 Last Name:
 Email (Required if office contact is provided):

Prescriber REMS Agreement

By signing below, you signify your understanding of the risks of Adempas treatment and your obligation as an Adempas prescriber to educate your female patients about the Adempas REMS, monitor them appropriately, and report any pregnancies to the Adempas REMS. Specifically, you attest to the following:

- I have reviewed the *Adempas Prescribing Information*, and the *Prescriber and Pharmacy Guide*.
- For all Females, I will:
 - determine the reproductive potential status of all female patients using the definitions provided in the *Prescriber and Pharmacy Guide*.
 - advise all females that Adempas is only available through a restricted distribution program called the Adempas REMS.
 - enroll all female patients into the Adempas REMS by completing the *Patient Enrollment Form* and submitting it to the REMS.
- For Females of Reproductive Potential, I will:
 - counsel Females of Reproductive Potential (FRP) on Adempas risks, including serious birth defects; and review the *Guide for Female Patients* with the patient.
 - counsel each FRP to immediately contact her prescriber if she misses a menstrual period or suspects pregnancy.
 - order and review pregnancy tests for FRPs before the start of treatment, monthly during treatment, and for one month after stopping treatment.
 - counsel each FRP to use effective contraception during Adempas treatment, and for one month after stopping treatment, and discuss her medical options in the event of unprotected sexual intercourse or known or suspected contraceptive failure using the *Guide for Female Patients*.
 - counsel each FRP during treatment if she is not complying with the required testing or if she is not using effective contraception, and to immediately contact her prescriber if she misses a menstrual period or suspects that she is pregnant.
- For Pre-pubertal Females, I will:
 - counsel the Pre-Pubertal Female (PPF) patient on the Adempas risks, including serious birth defects; and review the *Guide for Female Patients* with the patient.
 - for PPF, regularly assess the reproductive status of each pre-pubertal female during their treatment with Adempas.
 - at least annually document the reproductive potential status for Pre-Pubertal Females who are at least 8 years of age and older by submitting a *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form*.
- At all times, I will:
 - report any change or misclassification in reproductive status by submitting a *Change in Reproductive Potential Status and Pre-pubertal Annual Verification Form* within 10 business days of becoming aware of the change.
 - provide documentation of compliance with program requirements.
 - notify Bayer of any pregnancies at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

*Signature:

Please Validate your Submission by Re-entering your NPI Number, and pressing 'Submit Enrollment!':

Prescriber REMS Agreement for Those Who Dispense

I will:

- follow the requirements of a prescriber as I have attested to on the *Prescriber Enrollment and Agreement Form* above
- dispense Adempas to female patients only if the *Patient Enrollment and Consent Form* has been signed and submitted
- report dispensing Adempas to the REMS using the *Patient Enrollment and Consent Form*
- order and review a pregnancy test for FRP prior to dispensing Adempas
- not distribute, transfer, loan or sell Adempas
- maintain records of all processes and procedures including compliance with those processes and procedures
- comply with audits

Signature:

Please Validate your Submission by Re-entering your NPI Number, and pressing 'Submit Enrollment!':

Submit Enrollment

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact:
 Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com

Adempas REMS Enrollment - In-Patient Pharmacy...

Adempas Risk Evaluation and Mitigation Strategy (REMS) Program Inpatient Pharmacy Enrollment Form

Due to a risk of fetal exposure and adverse fetal outcomes in females of reproductive potential prescribed Adempas, Adempas is available only through the Adempas REMS. The Adempas REMS is a component of a Risk Evaluation and Mitigation Strategy (REMS). In order for inpatients to receive Adempas, females as well as inpatient pharmacies that wish to stock this product, must enroll in the Adempas REMS and agree to comply with the requirements of the program.

Access this form online at www.adempasREMS.com, fax this form to 1-855-662-5200 or call the Adempas REMS Program at 1-855-4ADEMPAS (1-855-423-3672).

Inpatient Pharmacy Information (* indicates required field)

* Type of Facility:	-- Please Select --
NPI:	1234567890
* Facility Name:	
* Address Line 1:	4408 16TH AVE
Address Line 2:	
* City:	BROOKLYN
* State:	NY
* Zip code:	11204-1012
* Phone:	718-871-6700
* Fax:	718-871-3043

Ship To Information (* indicates required field)

* Ship to Address:	-- Please Select --
* Ship to Contact Name:	

Authorized Representative Information (* indicates required field)

* First Name:	
Middle Initial:	
* Last Name:	
Position/Title:	-- Please Select --
Phone:	
Fax:	
* Email:	

Inpatient Pharmacy / Authorized Representative Acknowledgement

This inpatient pharmacy will:

- establish processes and procedures to ensure the REMS requirements are met.
- complete training in the Adempas REMS by reading the *Prescriber and Pharmacy Guide*.
- assume responsibility for the training of all relevant staff in dispensing on the Adempas REMS requirements, procedures, and Adempas REMS materials prior to dispensing Adempas, using the *Prescriber and Pharmacy Guide*.
- establish processes and procedures to verify the female patient is enrolled in the REMS or will be enrolled prior to discharge, her reproductive status, and the female patient is under the supervision and care of a certified prescriber.
- for females of reproductive potential: establish processes and procedures to verify pregnancy testing is complete and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately.
- before dispensing: verify the female patient is under the supervision and care of a certified prescriber, her reproductive status, and that she is enrolled or will be enrolled in the REMS prior to discharge through the processes and procedures established as a requirement of the REMS.
- for females of reproductive potential: verify pregnancy testing is complete, and that the patient is counseled on the risk of embryo-fetal toxicity, the need to use effective contraception, to get monthly pregnancy tests, and to inform the prescriber of a pregnancy immediately through the processes and procedures established as a requirement of the REMS.

At Discharge:

- verify the female patient is enrolled in the REMS through the processes and procedures established as a requirement of the REMS.
- dispense no more than a 15-day temporary supply of Adempas to any female patient upon discharge from the healthcare facility.

At all times:

- do not distribute, transfer, loan, or sell Adempas.
- report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.
- comply with audits by the manufacturer or a third party acting on behalf of the manufacturer to ensure all processes and procedures are in place and being followed.
- maintain records of all processes and procedures including compliance with those processes and procedures.

Note: If your inpatient pharmacy needs Adempas and is not certified in the Adempas REMS, contact the Adempas REMS Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672) for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment.

* Authorized Representative Signature:

Cancel

Submit

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact:
Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.